Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Consistency Lots Vaccine Study
This study has been completed.
Sponsored by: Merck
Information provided by: Merck
ClinicalTrials.gov Identifier: NCT00092456
  Purpose

This study was designed to evaluate consistency in the antibody response to three manufactured lots of an investigational Rotavirus Vaccine.


Condition Intervention Phase
Rotavirus Infections
Biological: rotavirus vaccine, live, oral, pentavalent
Phase III

MedlinePlus related topics: Rotavirus Infections
Drug Information available for: RotaTeq
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety Study
Official Title: Comparison of the Immunogenicity and Safety of Three Consistency Lots of V260 in Healthy Infants

Further study details as provided by Merck:

Primary Outcome Measures:
  • Serum neutralizing antibodies (SNA) against rotavirus; Risk of intussusception within 42 days following any dose [ Time Frame: 42 days following any dose ] [ Designated as safety issue: No ]

Enrollment: 784
Study Start Date: May 2003
Study Completion Date: September 2004
Intervention Details:
    Biological: rotavirus vaccine, live, oral, pentavalent
    Duration of Treatment: 1 year
  Eligibility

Ages Eligible for Study:   6 Weeks to 12 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy infants

Exclusion Criteria:

  • History of abdominal disorders from a birth defect, intussusception, or abdominal surgery
  • Known or suspected problems with the immune system
  • Fever at time of immunization
  • Prior administration of a rotavirus vaccine
  • History of known prior rotavirus disease, chronic diarrhea, or failure to thrive.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00092456

Sponsors and Collaborators
Merck
Investigators
Study Director: Medical Monitor Merck
  More Information

Responsible Party: Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences )
Study ID Numbers: 2004_078, V260-009
Study First Received: September 22, 2004
Last Updated: July 31, 2008
ClinicalTrials.gov Identifier: NCT00092456  
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Virus Diseases
Rotavirus Infections
Healthy

Additional relevant MeSH terms:
RNA Virus Infections
Reoviridae Infections
Infection

ClinicalTrials.gov processed this record on January 14, 2009